By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics and Cephalon have signed an agreement to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study, Myriad announced after the close of the market Wednesday.

Myriad said it will assess BRCA status in patients before they are enrolled in the study, but provided no other details about the study or Cephalon's candidate molecule. Financial and other terms of the agreement also were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.